SCHEDULE 13G/A: BlackRock Discloses 13.2% Stake in Integra LifeSciences Holdings Corp
Beneficial Ownership Report
BlackRock, Inc. has filed an amended Schedule 13G, reporting a beneficial ownership of 13.2% in Integra LifeSciences Holdings Corp. as of June 30, 2025.
Summary
- BlackRock, Inc. reported beneficial ownership of 10,282,705 shares of common stock in Integra LifeSciences Holdings Corp.
- This represents 13.2% of the total outstanding common stock of Integra LifeSciences Holdings Corp.
- BlackRock holds sole voting power over 10,115,629 shares and sole dispositive power over 10,282,705 shares.
- The filing is an Amendment No. 17 to a Schedule 13G, indicating a passive investment.
- One of BlackRock's entities, iShares Core S&P Small-Cap ETF, is noted to have an interest exceeding 5% of the total outstanding common stock.
- The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: The document is a factual regulatory filing disclosing beneficial ownership, which inherently has a neutral tone. The presence of a large institutional investor can be seen as a positive signal, but the filing itself does not convey explicit positive or negative sentiment regarding the issuer's performance.
Positives
- A large institutional investor like BlackRock holding a significant stake (13.2%) can signal confidence in the company's long-term prospects.
- The passive nature of the investment (Schedule 13G) suggests BlackRock is not seeking to influence control, which can provide stability.
Risks
- No specific risks related to Integra LifeSciences Holdings Corp. are detailed in this ownership disclosure. The filing itself is a standard regulatory disclosure.
Future Outlook
This Schedule 13G filing is a disclosure of current beneficial ownership and does not contain forward-looking statements or guidance regarding Integra LifeSciences Holdings Corp.'s future performance or BlackRock's investment strategy beyond the passive nature of the holding.
Management Comments
- The filing includes a certification from BlackRock, Inc. stating that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
Industry Context
This filing is a standard regulatory disclosure of a significant passive ownership stake by a major institutional investor in a healthcare company. It does not provide specific insights into broader industry trends or competitive dynamics within the medical devices sector, beyond indicating continued institutional interest.
Comparison to Industry Standards
- This document is a regulatory filing detailing an ownership stake and does not provide financial or operational results for comparison to industry standards or specific comparable companies or projects.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Attorney-in-fact for SEC filings (BlackRock, Inc.) | NA | Eric Andruczyk | 2025-01-21 | Authorization for SEC filing purposes via Power of Attorney. |
| Attorney-in-fact for SEC filings (BlackRock, Inc.) | NA | Richard Cundiff | 2025-01-21 | Authorization for SEC filing purposes via Power of Attorney. |
| Attorney-in-fact for SEC filings (BlackRock, Inc.) | NA | R. Andrew Dickson, III | 2025-01-21 | Authorization for SEC filing purposes via Power of Attorney. |
| Attorney-in-fact for SEC filings (BlackRock, Inc.) | NA | Spencer Fleming | 2025-01-21 | Authorization for SEC filing purposes via Power of Attorney. |
| Attorney-in-fact for SEC filings (BlackRock, Inc.) | NA | Laura Hildner | 2025-01-21 | Authorization for SEC filing purposes via Power of Attorney. |
| Attorney-in-fact for SEC filings (BlackRock, Inc.) | NA | David Maryles | 2025-01-21 | Authorization for SEC filing purposes via Power of Attorney. |
| Attorney-in-fact for SEC filings (BlackRock, Inc.) | NA | Christopher Meade | 2025-01-21 | Authorization for SEC filing purposes via Power of Attorney. |
| Attorney-in-fact for SEC filings (BlackRock, Inc.) | NA | Charles Park | 2025-01-21 | Authorization for SEC filing purposes via Power of Attorney. |
| Attorney-in-fact for SEC filings (BlackRock, Inc.) | NA | James Raby | 2025-01-21 | Authorization for SEC filing purposes via Power of Attorney. |
| Attorney-in-fact for SEC filings (BlackRock, Inc.) | NA | Daniel Riemer | 2025-01-21 | Authorization for SEC filing purposes via Power of Attorney. |
| Attorney-in-fact for SEC filings (BlackRock, Inc.) | NA | David Rothenberg | 2025-01-21 | Authorization for SEC filing purposes via Power of Attorney. |
| Attorney-in-fact for SEC filings (BlackRock, Inc.) | NA | Brenda Schulz | 2025-01-21 | Authorization for SEC filing purposes via Power of Attorney. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney Update | BlackRock, Inc. executed a new Power of Attorney on January 21, 2025, revoking a previous one dated April 30, 2023. This authorizes specific individuals to execute SEC filings on behalf of BlackRock and its subsidiaries. | 2025-01-21 | This is an internal corporate governance update for BlackRock, Inc. to streamline its SEC filing processes, and does not directly impact the corporate governance of Integra LifeSciences Holdings Corp. |
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional stake by BlackRock provides transparency regarding the ownership structure and may influence investor perception and confidence.
- Management: Awareness of a large passive institutional holder may influence management's focus on long-term value creation, though no direct influence is stated.
Next Steps
- The document does not outline any specific future actions, events, or milestones for Integra LifeSciences Holdings Corp. or BlackRock's investment strategy beyond the ongoing passive holding.
Key Dates
| Date | Description |
|---|---|
| 2023-04-30 | Previous Power of Attorney date, which was revoked. |
| 2025-01-21 | Effective date of the new Power of Attorney for BlackRock, Inc. |
| 2025-06-30 | Date of event which requires filing of this statement (reporting period end date). |
| 2025-07-17 | Signature date of the Schedule 13G filing by BlackRock, Inc. |
Keywords
BlackRock, Integra LifeSciences Holdings Corp, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, Passive Investment, Healthcare, Medical Devices
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.